welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Celecoxib, DFMO combination improved adenoma burden in patients with familial adenomatous polyposis
In a randomized clinical chemoprevention trial, a combination of celecoxib and diflouromethylornithine resulted in a nonsignificant benefit among patients with familial adenomatous polyposis when adenoma count in a defined area was used as the primary endpoint. However, the combination was well tolerated, and a secondary measure of adenoma burden using a video-based global assessment showed a significant incremental benefit.
expertly curated content related to this topic
-
Cancer Prevention Pharmaceuticals, Inc. and Tillotts Pharma AG Sign Licensing Agreement for CPP-1X/sulindac in Europ...Cancer Prevention Pharmaceuticals, Inc. ...
-
Scott K. Kuwada, MDScott K. Kuwada, MD joined The Queen’s...
-
Steven H. Itzkowitz, MDDr. Itzkowitz is past Chair of the Gastr...
-
Surveillance of Duodenal Polyposis in Familial Adenomatous Polyposis: Should the Spigelman Score Be Modified?BACKGROUND: Duodenal polyposis is a mani...
-
Rectal Epithelial Apoptosis in Familial Adenomatous Polyposis Patients Treated with SulindacBACKGROUND : Sulindac regresses colorect...
-
Single-Incision Laparoscopic Ileal Pouch-Anal Anastomosis in Children–How Does it Compare to a Laparoscopic-As...BACKGROUND : Although single-incision la...
-
Teamwork Makes a Life-Changing Difference for Luishttps://www.youtube.com/watch?v=bpnoHHL0...
English
Portuguese
Spanish